About Shandong Sito Bio-technology Company

The company was founded in 2010, with research and development and production of steroidal drug intermediates as its main business, and was successfully listed on the Shenzhen Stock Exchange in 2017. The company is based on the cutting-edge field of biopharmaceuticals. After years of independent research and development and technology introduction, the company pioneered large-scale application of biopharmaceutical technology in the field of steroidal drugs. It is a biomedical high-tech enterprise that applies genetic engineering technology and microbial transformation technology, and specializes in R&D and production of novel steroidal raw materials. The company is committed to providing high-quality drugs and raw materials that are “domestic leading and in line with the world”. It is committed to developing and producing raw materials for steroidal drugs using genetic engineering technology and microbial transformation technology, and has gradually developed into a leading supplier of steroidal drug raw materials. The main products are: androstenedione (AD), androstenedione (ADD), 9-hydroxyandrostenedione (9OH-AD), 17α-hydroxyprogesterone derivative (A ring), dialcohol (BA), fluticasone propionate, triamcinide, budesonide, mometasone furoate, fluticasone acetate, abiraterone acetate, triamcinide injection, glutathione (sterile powder and aqueous solution for injection), aluminum sucrose gel, methylprednisolone (sterile sodium succinate) Powders and aqueous solutions for injections), calcitonin injections, amikacin (ointments, injections), atracuronium injections, etc. Corporate honors: High-tech enterprise certificate, Shandong Engineering Laboratory, shortlisted in the fifth batch of green manufacturing lists of the General Office of the Ministry of Industry and Information Technology of Shandong Province, and awarded as a leading enterprise in the top ten industrial clusters in Shandong Province.